Trexquant Investment LP raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 114.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 203,909 shares of the company's stock after buying an additional 108,986 shares during the quarter. Trexquant Investment LP's holdings in Teva Pharmaceutical Industries were worth $3,134,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the stock. Menora Mivtachim Holdings LTD. grew its position in shares of Teva Pharmaceutical Industries by 2.8% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock worth $448,640,000 after buying an additional 808,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 1.2% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after buying an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Teva Pharmaceutical Industries by 197,885.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after buying an additional 22,044,407 shares during the period. Duquesne Family Office LLC grew its position in shares of Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the period. Finally, Janus Henderson Group PLC grew its position in shares of Teva Pharmaceutical Industries by 40.6% in the 4th quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company's stock valued at $148,497,000 after purchasing an additional 1,945,688 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
TEVA has been the topic of a number of analyst reports. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $24.71.
Read Our Latest Analysis on TEVA
Teva Pharmaceutical Industries Price Performance
Shares of Teva Pharmaceutical Industries stock traded up $0.46 during trading hours on Friday, reaching $18.94. The company's stock had a trading volume of 7,802,703 shares, compared to its average volume of 9,725,214. The stock has a market cap of $21.72 billion, a P/E ratio of -118.35, a P/E/G ratio of 1.09 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a 50 day moving average price of $17.04 and a 200-day moving average price of $16.40. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries's quarterly revenue was up .3% compared to the same quarter last year. During the same period last year, the company earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.
Insider Buying and Selling at Teva Pharmaceutical Industries
In related news, insider Placid Jover sold 6,053 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
